Infection Surveillance Solutions Market By Component (Software, Services); By Deployment Model (On-Premise, Cloud-Based); By End User (Hospitals and Clinics, Public Health Agencies, Long-Term Care Facilities); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Infection Surveillance Solutions Market: Production-Grade AUR Reporting and EHR Competition Shift Revenue Toward Validated Surveillance Platforms

The Global Infection Surveillance Solutions Market is estimated to reach USD 1.51 billion in 2025 and is projected to grow to USD 3.46 billion by 2032, expanding at a CAGR of 12.6%, driven by hospital-acquired infection monitoring, real-time surveillance software, antimicrobial resistance tracking, healthcare analytics, infection control systems, and public health reporting, according to Strategic Market Research.

 

The Infection Surveillance Solutions Market has moved beyond basic electronic infection tracking in developed healthcare systems. CDC’s National Healthcare Safety Network already connects approximately 25,000 medical facilities for HAI surveillance. Future spending will come primarily from replacing legacy platforms, automating regulatory submissions, adding antimicrobial-use and resistance modules, connecting more clinical data sources, and standardizing surveillance across multi-hospital systems.

 

The market follows a preventive-care, monitoring, public-health reporting, and healthcare-IT pathway. Hospitals purchase these systems to identify reportable infections, calculate device-day and patient-day denominators, monitor antimicrobial use, investigate transmission clusters, and document interventions. Revenue is generated through software subscriptions or licenses, implementation, interfaces, configuration, data migration, training, support, and regulatory updates.

 

Infection counts should not be treated as direct software demand. Hospitals can use specialist surveillance platforms, EHR-native modules, public-health portals, internal databases, or partially manual processes. Suppliers capture premium revenue when they solve functions that hospitals cannot reproduce easily, particularly validated NHSN reporting, cross-system data normalization, automated case prioritization, and enterprise workflow governance.

 

The 2026 AUR Conversion Creates a Defined Implementation Market

The strongest near-term U.S. demand trigger is the transition from preliminary participation to validated antimicrobial-use and resistance reporting. CMS separated the combined AUR measure into distinct Antimicrobial Use and Antimicrobial Resistance measures for the 2025 EHR reporting period. Hospitals that used the pre-production and validation pathway in 2025 must move into validated production reporting in 2026 unless they qualify for an exclusion.

Production reporting requires continuous data exchange rather than a one-time test submission. Antimicrobial-use files depend on medication administration, patient location, and denominator data. Resistance reporting requires microbiology results, organism identification, susceptibility interpretation, and encounter information. Hospitals must connect pharmacy, laboratory, admission-discharge-transfer, and EHR systems before they can submit reliable data.

The implementation pool has expanded quickly. As of January 1, 2025, 4,362 hospitals, equal to 59.1% of eligible facilities, had submitted at least one month of antimicrobial-use data to NHSN. Participation ranged from 27% in Puerto Rico to 83% in Maine. The remaining hospitals do not represent an automatic commercial opportunity because some qualify for exclusions or use EHR-native tools. They do, however, form a substantial pool of facilities facing interface, validation, and staffing barriers.

The technical burden protects implementation and service revenue. In 2024, 81% of U.S. hospitals reported at least one difficulty with electronic public-health reporting. Challenges affected 57% of hospitals engaged in AUR reporting, while 55% cited technical complexity involving interfaces, transmission, or submission. Standards have expanded electronic reporting, but they have not removed the need for mapping, testing, exception management, and ongoing data-quality support.

Hospitals also face payment exposure. Facilities in the worst-performing quartile under the Hospital-Acquired Condition Reduction Program receive a 1% Medicare payment reduction. Infection-surveillance software cannot independently prevent that adjustment, but inaccurate denominators, missed cases, or failed submissions can weaken the hospital’s ability to manage its performance. Surveillance platforms are therefore evaluated as quality and compliance infrastructure rather than optional analytics.

 

FHIR Reduces Interface Lock-In but Raises the Value of Data Management

CDC’s migration toward FHIR-based digital quality measures will change the cost structure of infection surveillance. NHSNLink is an open-source application designed to exchange hospital data with NHSN through FHIR. Digital quality measures are intended to automate patient-level reporting and reduce delays in data collection.

FHIR creates immediate implementation work. Hospitals must assess API readiness, map local data to standardized resources, validate extracted records, and assign internal staff to maintain the connection. CDC guidance states that facilities need designated personnel to support initial preparation and continuing FHIR reporting. The technology standardizes transport, but hospitals remain responsible for the completeness and validity of their data.

Standardized exchange will gradually reduce the premium attached to proprietary interfaces. Specialist vendors that depend mainly on custom data extraction may face margin pressure as EHRs and public-health agencies make standard connectivity more accessible. Competitive value will move toward clinical rule management, exception handling, attribution accuracy, auditability, and multi-site governance.

This change benefits established vendors that can operate above the interface layer. A hospital may retrieve microbiology or medication data through FHIR without a specialist platform, but it still needs to reconcile inconsistent location codes, duplicate events, missing data, procedure attribution, and annual NHSN rule changes. Suppliers that manage those problems can retain recurring value after standardized data transport becomes common.

 

Staffing Shortages Turn Labor Savings into a Buying Requirement

An analysis of 390 hospitals found that 79.2% reported infection-prevention staffing below the level predicted by the APIC staffing model. The median ratio was approximately one infection preventionist for every 121 occupied beds. Infection-prevention teams must still perform surveillance, outbreak investigation, education, audits, regulatory reporting, and intervention follow-up despite those staffing gaps.

Hospitals will pay for automation when it removes measurable work. High-value functions include narrowing the number of records requiring review, automating denominator calculations, identifying duplicate events, prioritizing likely reportable cases, and producing submission-ready files. Software that generates large alert queues without improving specificity transfers work rather than eliminating it.

Product evaluations increasingly focus on documented time release. Wolters Kluwer reported that Pratt Regional Medical Center recovered approximately ten staff hours each week after implementing Sentri7 Infection Prevention. The result is a customer case rather than a market-wide benchmark, but it shows the evidence hospitals now expect from suppliers competing for limited quality and IT budgets.

 

Specialist Vendors Compete on Installed Base, Reporting Depth, and Module Expansion

The supplier landscape includes specialist clinical-surveillance companies, diversified medical-technology manufacturers, EHR vendors, public-health platforms, and genomic-surveillance providers. These companies do not compete on identical terms. Specialist platforms depend on recurring subscriptions and interfaces. EHR vendors can bundle infection control into larger enterprise contracts. Diagnostics and sequencing suppliers earn revenue from data-generating instruments, reagents, and laboratory workflows.

 

Wolters Kluwer Uses a 700-Hospital Base to Expand Across Surveillance Modules

Wolters Kluwer’s Sentri7 platform is used by more than 700 U.S. hospitals. The platform combines Infection Prevention, Pharmacy Surveillance, and Drug Diversion on the SoleSource architecture. This installed base gives Wolters Kluwer a cross-selling advantage because infection prevention, antimicrobial stewardship, and pharmacy surveillance use overlapping EHR, microbiology, and medication data.

Sentri7 Infection Prevention supports HAI identification, trend analysis, patient movement tracking, and NHSN reporting. The company received Best in KLAS recognition for Infection Control and Monitoring in both 2025 and 2026. In 2026, Sentri7 was also recognized for Pharmacy Surveillance, reinforcing its positioning as a broader clinical-surveillance platform rather than a single-department product. Vendor-sponsored awards do not establish market share, but repeated recognition can influence hospital shortlists and renewal decisions.

Wolters Kluwer’s competitive advantage is the ability to distribute integration and support costs across several modules. A hospital that already uses Sentri7 for pharmacy surveillance can add infection-prevention functionality without implementing an entirely separate data platform. Bundling may reduce individual module prices, but it increases total account value and raises switching costs.

 

Premier Uses TheraDoc to Protect a Long-Standing Hospital Base

Premier’s TheraDoc platform combines infection prevention, antimicrobial stewardship, pharmacy surveillance, and electronic public-health reporting. The latest readily verifiable product-specific installed-base number published by Premier is an older 2017 disclosure stating that TheraDoc was used by more than 1,000 U.S. hospitals. That figure should not be treated as the current installed base, but it demonstrates that TheraDoc entered the present replacement cycle with a substantial historical footprint.

Premier continues to update the product’s certified reporting infrastructure. TheraDoc versions 5.4.7, 5.4.8, and 5.4.9 received certification updates between August 2025 and June 2026. Premier’s certification disclosures identify one-time data-acquisition or implementation charges alongside recurring functionality, training, and support fees. Regulatory maintenance therefore supports both project-based revenue and annual recurring revenue.

The historical hospital base provides replacement and module-expansion opportunities, but it also creates modernization risk. Older TheraDoc deployments may compete against newer cloud platforms or EHR-native infection-control tools during hospital IT consolidation. Premier must protect those accounts through reporting reliability, migration support, and integration with its wider PINC AI data and performance portfolio.

 

Inovalon Is Expanding VigiLanz from Surveillance Product to Provider Platform

Inovalon acquired VigiLanz in February 2024, bringing a SaaS clinical-surveillance and patient-safety company into its Provider Cloud portfolio. The acquisition strengthens Inovalon’s access to hospital clinical data and creates cross-selling opportunities across infection prevention, antimicrobial stewardship, pharmacy surveillance, safety reporting, and quality management.

Inovalon now markets VigiLanz Infection Prevention and the higher-configuration Infection Prevention Pro product. The platform uses rule-based analytics to convert hospital data into near-real-time alerts, support outbreak management, and organize infection-prevention workflows. A tiered product structure allows Inovalon to serve hospitals with different levels of complexity while creating an upgrade path for larger systems.

The company does not publicly disclose a current VigiLanz-wide hospital count in the reviewed materials. Customer evidence nevertheless shows multi-facility use. More than 20 Adventist Health medical centers have used VigiLanz to support HAI reduction and antimicrobial optimization. A separate PIH Health case reported that the platform identified 50% more community-onset infections. That distinction can improve attribution and prevent facilities from classifying externally acquired infections as hospital events. Both figures are vendor-reported customer results rather than independent market benchmarks.

The acquisition raises pressure on smaller independent surveillance suppliers. Inovalon can combine VigiLanz workflows with broader provider data, analytics, and cloud services. Hospitals may prefer a vendor capable of supporting several clinical and administrative functions under one commercial relationship, especially where cybersecurity reviews and interface maintenance increase the cost of each additional supplier.

 

BD Connects Infection Surveillance with Diagnostics and Medication Management

BD participates through BD HealthSight Infection Advisor with MedMined Insights. The hosted platform aggregates and normalizes microbiology, laboratory, pharmacy, and clinical data. It applies the Nosocomial Infection Marker algorithm to identify infection patterns and supports near-real-time alerts and regulatory reporting.

BD’s position differs from that of a software-only vendor. The company can connect infection analytics with microbiology systems, medication-management technologies, diagnostics, and antimicrobial-stewardship workflows. This creates opportunities to sell surveillance as part of a broader hospital infection and medication-management architecture rather than as an isolated IT product.

Public product certification materials confirm a one-time implementation charge and an annual licensing fee for BD’s AUR reporting capability. The structure provides direct evidence that infection-surveillance revenue combines deployment income with recurring software payments.

BD does not disclose a current product-specific installed-base number for HealthSight Infection Advisor in the reviewed sources. Customer evidence includes a Hackensack Meridian–JFK Medical Center case reporting a 48% year-over-year decline in C. difficile infection rates after workflow changes supported by BD tools. A Lane Regional Medical Center case reported nearly four hours per month saved in NHSN classification and submission work. These outcomes are facility-specific and involve clinical process changes in addition to the software. They remain commercially relevant because they give BD measurable evidence for labor and infection-reduction discussions.

 

Epic Creates the Largest EHR-Native Substitution Threat

Epic’s Bugsy application embeds infection surveillance directly into the EHR. Infection preventionists can use it to maintain surveillance, analyze trends, and report hospital-acquired infections to regulators. Epic states that its software is used by 3,300 hospitals and 73,000 clinics. That figure is the overall Epic footprint, not Bugsy adoption, but it defines the potential distribution base for an embedded infection-control module.

Epic can reduce the need for separate interfaces, user administration, cybersecurity reviews, and supplier contracts. Hospitals moving to an enterprise-wide Epic environment may accept Bugsy even when a specialist platform offers more advanced functions because the EHR module lowers total IT complexity.

Specialist vendors remain relevant in health systems operating multiple EHRs or requiring surveillance functions that Bugsy does not adequately support. Their strongest defence is cross-EHR standardization, deeper reporting workflows, superior case prioritization, or specialized outbreak analytics. The competitive risk increases after a hospital completes a single-EHR migration.

 

Oracle Health Bundles Infection Control and AUR into the Clinical Suite

Oracle Health offers EHR-integrated Infection Control and Antimicrobial Usage and Resistance Reporting. The infection-control module provides near-real-time worklists and dashboards for HAIs, multidrug-resistant organisms, reportable diseases, surgical procedures, isolation orders, and NHSN location mapping. Its AUR product supports electronic uploads to NHSN and aligns reporting with CMS interoperability requirements.

Oracle does not publish a current product-specific customer count for Infection Control or AUR Reporting. Its advantage comes from bundling these functions with the broader Oracle Health EHR, microbiology, pharmacy, laboratory, and public-health reporting suite. Hospitals already operating Oracle Health can add surveillance capabilities without establishing a separate data architecture.

Oracle and Epic place direct pressure on specialist vendors where hospitals prioritize supplier consolidation. Their embedded model can reduce standalone software spending even when specialist products retain deeper functionality. Independent suppliers must prove that additional subscription and integration costs produce measurable improvements beyond the EHR module.

 

Baxter ICNET Targets Hospital and Regional Surveillance Networks

Baxter’s ICNET platform includes a Hospital Suite for facility-level infection prevention and antimicrobial stewardship and a National Suite for population-level surveillance, outbreak management, and public-health programs. The two-layer product structure enables Baxter to compete for hospital deployments, regional contracts, and national surveillance infrastructure.

Dorset’s county-wide use of ICNET across multiple NHS organizations demonstrates the value of regional standardization. A shared platform can apply consistent infection definitions and support cross-organization analysis. It also produces higher switching costs because several institutions depend on the same data architecture, workflows, and reporting rules.

Baxter has not published a current global ICNET installation count in the reviewed sources. Its strongest competitive position is in health systems and public-health structures that need surveillance above the level of an individual hospital. This differentiates ICNET from products designed mainly for U.S. NHSN submissions.

 

Illumina Extends Surveillance into the Genomic Layer

Illumina should be treated as an adjacent genomic-surveillance supplier rather than a direct competitor to Sentri7, TheraDoc, or VigiLanz. Its HAI surveillance offering includes sequencing instruments, DNA preparation workflows, reagents, and analysis tools used to characterize pathogens, resistance genes, and transmission relationships.

Conventional hospital surveillance may show that several patients carry the same organism. Whole-genome sequencing can determine whether isolates are closely related enough to indicate transmission. This distinction can alter outbreak response, environmental testing, ward closure decisions, and contact investigation. Genomic data therefore increases the analytical depth of infection-surveillance programs.

Illumina’s commercial opportunity grows when hospitals, reference laboratories, and public-health agencies incorporate sequencing into routine investigation of multidrug-resistant organisms, Candida auris, and unresolved clusters. Revenue flows through instruments, consumables, sequencing workflows, and analysis rather than infection-reporting subscriptions. Illumina states that its microbial whole-genome sequencing workflows can analyze hundreds of organisms through multiplexing. Its HAI materials are primarily designated for research use, which limits direct clinical claims and reinforces the need for validated laboratory and regulatory pathways.

 

Platform Consolidation Raises Customer Value and Competitive Barriers

The market is consolidating around platforms that combine infection prevention, antimicrobial stewardship, pharmacy surveillance, patient safety, and public-health reporting. These functions use many of the same laboratory, medication, encounter, and location data. Suppliers can distribute integration costs across more modules and increase annual revenue per hospital.

Hospital buyers benefit from fewer interfaces and contracts, but module bundling changes pricing. Vendors may offer lower prices for individual applications when the hospital purchases a broader suite. Total account value rises, while the cost of replacing the platform increases because several departments depend on it.

Point-solution vendors face the greatest pressure. A basic dashboard, infection list, or rules engine can be replicated through an EHR, internal data warehouse, open-source application, or government portal. A standalone supplier needs defensible accuracy, faster implementation, managed reporting, genomic integration, or outbreak functionality that enterprise platforms do not provide.

 

Supplier Continuity Has Become a Procurement Variable

Oxford University Hospitals reported that its infection-surveillance supplier ceased trading. A subsequent laboratory-system change removed the existing interface and reduced real-time surveillance. The microbiology team had to provide daily reports while the trust sought funding for a replacement platform.

The case demonstrates that low software pricing does not equal low ownership cost. Supplier failure can interrupt alerts, historical trends, reporting workflows, and outbreak investigation. Procurement teams are therefore placing more weight on vendor financial stability, data-export rights, interface ownership, disaster recovery, migration support, and contractual service continuity.

Replacement projects also create substantial services revenue. An incoming supplier must extract historical data, rebuild feeds, reconcile location structures, validate reporting rules, retrain users, and operate parallel workflows before the old system can be retired. EHR and laboratory migrations can trigger the same work even when the surveillance vendor remains unchanged.

 

Pricing Power Is Moving Away from Basic Software Features

Public list prices and average enterprise contract values remain limited because hospitals negotiate according to facility count, interfaces, modules, implementation scope, users, and support requirements. Available vendor disclosures show a consistent structure: one-time implementation and data-acquisition charges combined with annual software, training, maintenance, and regulatory-support fees.

Premium pricing is most defensible for:

• Validated NHSN and AUR reporting

• Pharmacy, laboratory, and EHR integration

• Cross-EHR data normalization

• Multi-hospital surveillance governance

• Automated denominator calculation

• High-specificity case prioritization

• Outbreak and contact-network analysis

• Historical-data migration

• Cybersecurity and service continuity

• Genomic surveillance integration

Static dashboards and basic alerting are becoming commoditized. FHIR, EHR-native modules, internal analytics, and public-health portals reduce the value of proprietary data transport. Suppliers that manage clinical interpretation and reporting quality can retain recurring revenue after interface costs decline.

 

Strategic Market Outlook

The strongest near-term opportunity is the conversion of complex reporting workflows into validated production systems. The 2026 AUR transition creates a defined implementation cycle. NHSN’s FHIR migration adds new integration and validation work while reducing long-term dependence on proprietary interfaces.

Wolters Kluwer and Premier enter this cycle with publicly reported hospital footprints of more than 700 and historically more than 1,000 facilities, respectively. Inovalon is using its 2024 VigiLanz acquisition to build a wider provider-surveillance platform. BD can connect surveillance with diagnostics and medication-management infrastructure. Epic and Oracle threaten standalone contracts through EHR bundling. Baxter is positioned for regional and public-health deployments, while Illumina expands the market into genomic outbreak investigation.

The strongest suppliers will combine regulatory maintenance, cross-system integration, measurable labor savings, multi-module workflows, and dependable service continuity. Products limited to infection lists and dashboards will lose pricing power. Revenue will concentrate in validated reporting, enterprise standardization, clinical data quality, and advanced outbreak analysis.

 

Infection Surveillance Solutions Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.51 Billion
Revenue Forecast in 2032	USD 3.46 Billion
Overall Growth Rate	CAGR of 12.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Component	Software; Services
By Deployment Model	On-Premise; Cloud-Based
By End User	Hospitals and Clinics; Public Health Agencies; Long-Term Care Facilities
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Customization Option	Available upon request